Huck constance

Radiation oncologist @InstitutBergonié

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)

Full text: https://t.co/2ziB2Z24ES

@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

[Chad Tang, MD @ChadTangMD]

Using individual patient data we found strong evidence of benefit across endpoints: PFS, radiographic PFS (rPFS), and castration resistance free survival (CRFS). Overall survival (OS) barely missed significance with P=0.051 in the mixed effect model

[UroToday.com @urotoday]

Examining guidelines on radiotherapy for #BladderCancer with carcinoma in situ. @ConstanceHuck joins @UroDocAsh to examine whether carcinoma in situ should contraindicate trimodality therapy for muscle-invasive bladder cancer. The conversation highlights how historical data showing poor outcomes with CIS may be outdated, as older studies used split-course radiotherapy and inferior imaging techniques. #WatchNow on UroToday to learn more > https://t.co/FzLuRTa5ik

[RadiotherapieFr @radiotherapiefr]

"On ne ressent aucune douleur" : qu'est-ce que la #radiothérapie #stéréotaxique, cette méthode innovante qui soigne les #cancers masculins ? #CancerDeLaProstate @ConstanceHuck @Achard_Verane #CancerDeLaVessie #MedPhys #RadOncNews | #hcsmeufr @scoopit https://t.co/TX29lMNf1F

[Huck constance @ConstanceHuck]

Commented in EUO on RAMPP trial:

• 💊 Limited modern systemic Tx
• 🔍 Stage-migration with PSMA PET
• ⏸️ Early stop → underpowered CSM signal
• ⚠️ Higher morbidity vs RT

➡️ 🎯 RT remains the most evidence-based local option in oligometastatic HSPC.

[Paul Sargos @PaulSargos]

@ConstanceHuck, @AlbertoBossial
⚠️RAMPP trial :

🔑 If Local control of the primary tumor is beneficial, The optimal modality remains undefined!

🔑 RT currently represents the evidence-based, less morbid SOC until randomized data demonstrate otherwise

https://t.co/FHRAXPgFqF

[UroToday.com @urotoday]

Adjuvant radiotherapy evaluated for high-risk #BladderCancer after cystectomy. @VedangMurthy @TataMemorial joins @l_ballas @CedarsSinai presenting BART trial results, demonstrating adjuvant pelvic radiotherapy benefits for high-risk post-cystectomy bladder cancer patients. #WatchNow > https://t.co/dw2TqLIGct

[Enrique Grande @drenriquegrande]

🧪 Progress for bladder-sparing in MIBC:
An international consensus standardizes clinical complete response (cCR) and endorses event-free survival (EFS) as the key endpoint for next-gen perioperative trials.

#BladderCancer @JCO_ASCO
https://t.co/TkRRORlEIi

[Genevieve LOOS @GenevieveLOOS12]

What the best approach for BCG-unresponsive NMIBC ?
If you are worried about the expenses like Donald Trump or @MRoupret, think about Radiation Therapy like @Achard_Verane !! #focus2025

[Daniel E Spratt @DrSpratticus]

GU005 allowed hotspots of 38.7 Gy. PACE-B allowed hotspots of 48-50 Gy.

So there is a 13 Gy eqd2 difference even between prescription doses and even more when accounting for hotspots.

Thus GU005 had a bit more BCR but lower tox. PACE-B had a little better BCR and more tox.

Just dose

[Shankar Siva @_ShankarSiva]

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo:
🔹 RT (n=77) vs Obs (n=76)
🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006)
🔹OS trend ↑RT (68% vs 57%), not sig
🔹No ↑ severe late adverse events
👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc

[Daniel E Spratt @DrSpratticus]

#astro25

@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.

Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased

3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.

Goodbye WPRT

[Paul Sargos @PaulSargos]

✨Our '' rising '' star, @ConstanceHuck
discussing TMT in the context of CIS, with @UroDocAsh.

👂Listen this excellent discussion here @urotoday
following the paper published in @EUplatinum

https://t.co/loh4kbsQU1

[Andrea Necchi @AndreaNecchi]

📫 Interim results of #Sunrise4 are released @TheLancetOncol
Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC
✅ TAR200+CET: pCR 42%, Major path Response 60%
✅ in cT2 pts baseline: pCR 48%
✅ TAR200 exposure-response association: pCR 50% if TAR200x4 full cycles
Can we cure selected pts with MIBC with intravesical Rx + single agent IO?

Future: is there a way to avoid #radicalcystectomy by consolidating Response with TAR200 in selected pts?

Primary results with full biomarker results are awaited

@Larvol @ASCO @myESMO @OncoAlert @urotoday @Medscape @SanRaffaeleMI @MyUniSR @JNJNews @spsutkaMD @DrFelixGuerrero @evanguelosx @BenjaminPradere
#bladdercancer #clinicalresearch #MedTwitter #neoadjuvant

https://t.co/5qsL8sAxWr

[Paul Sargos @PaulSargos]

✍️🇫🇷
SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER
@SFjROfr

https://t.co/SKvHnAHM13

[Huck constance @ConstanceHuck]

🚨 MUST READ 🚨
🔥 Bladder preservation with CIS? Time to rethink the rules.

👉 New in EUO: https://t.co/Daj2uxZ0WB

🙏 Grateful to the amazing team!

#BladderCancer #Urology #RadiationTherapy #BladderPreservation #CIS

[Paul Sargos @PaulSargos]

How to manage gynecomastia with ARPIs monotherapy?
A review by @nassimVibert 🙏

https://t.co/K9X0rDjJ6C

#ProstateCancer #Prostate #life

[Huck constance @ConstanceHuck]

@AinhoaMada @EORTC Thanks Ainhoa! Great team work !

[Huck constance @ConstanceHuck]

New insights on SBRT in recurrent ovarian cancer – now in CTRO:
“SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review”
👉 https://t.co/AbnJgiAnoH

🎯 Local control
⏳ Delayed systemic therapy
⚖️ Personalized strategy
@EORTC

[Shankar Siva @_ShankarSiva]

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb!
➡️link https://t.co/VYvAn6kli1

[European Urology @EUplatinum]

EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al

Read the full update here: https://t.co/v6Z01NXKdr

#UroSoMe #MedTwitter #EurUrol #EAUGuidelines #GuidelinesUpdate